A Phase II Trial of TPF Induction Chemotherapy in cN2 OSCC Patients
Status:
Recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
To confirm the subgroup result from TPF (docetaxel, cisplatin and 5-fluorouracil ) trial
(NCT01542931) that cN2 OSCC patients could benefit from TPF induction chemotherapy compared
to the standard treatment.